Who are Hearticellgram-AMI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Cellular Matrix / A-CP-HA Kit, stem cells infusion, ACP, SkinTE, Stempeucel®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hearticellgram-ami.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hearticellgram-AMI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hearticellgram-AMI (Hearticellgram-AMI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Cardiovascular.

phase 3 Cell therapy Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

Hearticellgram-AMI (Hearticellgram-AMI) — Pharmicell Co., Ltd.. Hearticellgram-AMI is an autologous bone marrow-derived cell therapy that promotes cardiac regeneration and repair following acute myocardial infarction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hearticellgram-AMI TARGET	Hearticellgram-AMI	Pharmicell Co., Ltd.	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	Fundación Santiago Dexeus Font	marketed	Cell therapy / Regenerative medicine product
stem cells infusion	stem cells infusion	University of Campania Luigi Vanvitelli	marketed	Cell therapy
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
SkinTE	SkinTE	PolarityTE	marketed	Autologous cell therapy / Tissue-engineered product
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hearticellgram-AMI — Competitive Intelligence Brief. https://druglandscape.com/ci/hearticellgram-ami. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing